DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Lausanne : Frontiers Research Foundation]
    • Subject Terms:
      Gene Expression*; Carcinoma, Hepatocellular/*genetics ; Carcinoma, Hepatocellular/*therapy ; DNA Damage/*genetics ; DNA Repair/*genetics ; Immune Checkpoint Inhibitors/*therapeutic use ; Immunotherapy/*methods ; Liver Neoplasms/*genetics ; Liver Neoplasms/*therapy; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Carcinoma, Hepatocellular/mortality ; Child ; Child, Preschool ; Cohort Studies ; Drug Resistance, Neoplasm/genetics ; Female ; Humans ; Infant ; Infant, Newborn ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Prognosis ; Risk Factors ; Treatment Outcome ; Tumor Microenvironment/immunology ; Young Adult
    • Abstract:
      Immune checkpoint inhibitors(ICIs) that activate tumor-specific immune responses bring new hope for the treatment of hepatocellular carcinoma(HCC). However, there are still some problems, such as uncertain curative effects and low objective response rates, which limit the curative effect of immunotherapy. Therefore, it is an urgent problem to guide the use of ICIs in HCC based on molecular typing. We downloaded the The Cancer Genome Atlas-Liver hepatocellular carcinoma(TCGA-LIHC) and Mongolian-LIHC cohort. Unsupervised clustering was applied to the highly variable data regarding expression of DNA damage repair(DDR). The CIBERSORT was used to evaluate the proportions of immune cells. The connectivity map(CMap) and pRRophetic algorithms were used to predict the drug sensitivity. There were significant differences in DDR molecular subclasses in HCC(DDR1 and DDR2), and DDR1 patients had low expression of DDR-related genes, while DDR2 patients had high expression of DDR-related genes. Of the patients who received traditional treatment, DDR2 patients had significantly worse overall survival(OS) than DDR1 patients. In contrast, of the patients who received ICIs, DDR2 patients had significantly prolonged OS compared with DDR1 patients. Of the patients who received traditional treatment, patients with high DDR scores had worse OS than those with low DDR scores. However, the survival of patients with high DDR scores after receiving ICIs was significantly higher than that of patients with low DDR scores. The DDR scores of patients in the DDR2 group were significantly higher than those of patients in the DDR1 group. The tumor microenvironment(TME) of DDR2 patients was highly infiltrated by activated immune cells, immune checkpoint molecules and proinflammatory molecules and antigen presentation-related molecules. In this study, HCC patients were divided into the DDR1 and DDR2 group. Moreover, DDR status may serve as a potential biomarker to predict opposite clinical prognosis immunotherapy and non-immunotherapy in HCC.
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2021 Chen, Wang, Deng, Zhang, Liao, Li, Yang and Chen.)
    • References:
      J Hepatol. 2017 Mar;66(3):482-484. (PMID: 28011330)
      Bioinformatics. 2010 Jun 15;26(12):1572-3. (PMID: 20427518)
      Cell Metab. 2019 Jul 2;30(1):14-15. (PMID: 31269423)
      Bioinformatics. 2011 Jun 15;27(12):1739-40. (PMID: 21546393)
      Nanomedicine (Lond). 2010 Jun;5(4):597-615. (PMID: 20528455)
      Cancer Treat Rev. 2018 Feb;63:40-47. (PMID: 29207310)
      Expert Rev Anticancer Ther. 2018 Dec;18(12):1169-1175. (PMID: 30304963)
      Immunity. 2018 Apr 17;48(4):812-830.e14. (PMID: 29628290)
      Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. (PMID: 23180760)
      Nucleic Acids Res. 2016 May 5;44(8):e71. (PMID: 26704973)
      Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
      Nature. 2018 Feb 22;554(7693):544-548. (PMID: 29443960)
      Cell Death Dis. 2018 May 10;9(5):543. (PMID: 29749376)
      Eur Urol Focus. 2021 Nov;7(6):1339-1346. (PMID: 32861617)
      Front Psychol. 2017 Apr 05;8:511. (PMID: 28424648)
      Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648)
      Cell. 2016 Mar 24;165(1):35-44. (PMID: 26997480)
      Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
      Nat Immunol. 2018 Mar;19(3):222-232. (PMID: 29379119)
      Front Immunol. 2020 Aug 12;11:2039. (PMID: 32903444)
      Cell. 2017 Nov 30;171(6):1437-1452.e17. (PMID: 29195078)
      Oncotarget. 2015 Dec 8;6(39):42334-44. (PMID: 26517354)
      Nat Med. 2018 Oct;24(10):1550-1558. (PMID: 30127393)
      Dis Markers. 2019 Apr 4;2019:5702026. (PMID: 31089396)
      Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
      Nat Immunol. 2016 Jul;17(7):844-50. (PMID: 27213689)
      BMC Cancer. 2017 May 19;17(1):344. (PMID: 28526069)
      Nature. 2009 Nov 5;462(7269):108-12. (PMID: 19847166)
      Sci Transl Med. 2018 Jul 18;10(450):. (PMID: 30021886)
      Methods Mol Biol. 2018;1711:243-259. (PMID: 29344893)
      Cancer Res. 2018 Nov 15;78(22):6486-6496. (PMID: 30171052)
      Neoplasia. 2019 Jun;21(6):591-601. (PMID: 31055200)
      Nature. 2012 Jul 18;487(7407):330-7. (PMID: 22810696)
      Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846)
      Clin Cancer Res. 2017 Sep 1;23(17):4950-4958. (PMID: 28864723)
      J Clin Oncol. 2018 Jun 10;36(17):1685-1694. (PMID: 29489427)
      Liver Cancer. 2016 Nov;6(1):34-43. (PMID: 27995086)
      Biomed Res Int. 2014;2014:153867. (PMID: 24877058)
      Nature. 2014 Nov 27;515(7528):558-62. (PMID: 25428503)
      Nat Commun. 2020 Sep 1;11(1):4383. (PMID: 32873799)
      Immunity. 2016 May 17;44(5):1091-101. (PMID: 27192576)
      Cell. 2001 Aug 10;106(3):255-8. (PMID: 11509172)
      Drug Des Devel Ther. 2019 Jun 21;13:2021-2041. (PMID: 31417239)
      CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
      Bioinformatics. 2007 Dec 1;23(23):3251-3. (PMID: 17644558)
      Pharmacol Res. 2020 Sep;159:105028. (PMID: 32569820)
      Sci Rep. 2018 Nov 16;8(1):16951. (PMID: 30446676)
      Annu Rev Biochem. 2004;73:39-85. (PMID: 15189136)
      Asian Pac J Cancer Prev. 2014;15(6):2613-8. (PMID: 24761872)
      Science. 2006 Sep 29;313(5795):1929-35. (PMID: 17008526)
      Cancer Immunol Immunother. 2021 Jan;70(1):137-151. (PMID: 32653938)
    • Contributed Indexing:
      Keywords: DNA damage repair; Immune checkpoint inhibitors; hepatocellular carcinoma; immunotherapy; tumor microenvironment
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (Immune Checkpoint Inhibitors)
    • Publication Date:
      Date Created: 20210802 Date Completed: 20211026 Latest Revision: 20231107
    • Publication Date:
      20250114
    • Accession Number:
      PMC8320764
    • Accession Number:
      10.3389/fimmu.2021.676922
    • Accession Number:
      34335575